German gatekeeper backs Pfizer and BMS' Eliquis; Canadian court to allow Proscar class action;

@FiercePharma: U.S. Trade Rep weighs response to India's patent smackdown, after Novartis' loss on Glivec Monday. More | Follow @FiercePharma

@EricPFierce: Lilly is installing some new technology in its US insulin cartridge plant, to pump up output. Article | Follow @EricPFierce

> Germany's tough new pricing authority determined that Bristol-Myers Squibb ($BMY) and Pfizer's ($PFE) anticoagulant Eliquis delivers a "significant" additional benefit in stroke prevention for patients 65 and over, compared with warfarin or aspirin therapy. Report

> A Canadian judge will allow men to pursue class-action claims against Merck ($MRK) over sexual side effects of its drug finasteride, sold in the prostate treatment Proscar and baldness remedy Propecia. Report

> GlaxoSmithKline ($GSK) won approval for its four-strain influenza vaccine in Germany and the U.K. Release

> PhRMA and the Generic Pharmaceuticals Association advocated a federal track-and-trace system to secure the pharmaceutical supply chain. Report

Biotech News

@FierceBiotech: Elan closes $3.25B Tysabri deal and preps for biotech deal spree. News | Follow @FierceBiotech

@JohnCFierce: AstraZeneca's latest biotech deal offers more early-stage research work. Years away from PhIII, where it needs help. More | Follow @JohnCFierce.

@RyanMFierce: Pfizer made an another early-stage deal with a Cambridge, MA biotech. This one with Gates-backed Tetragenics. Release | Follow @RyanMFierce

> AstraZeneca gambles on cardio therapy in AlphaCore buyout. Report

> Resurgent Pfizer partners with Bind on new nanotech drug effort. News

> Biotech gamblers crowd high-stakes game for Sarepta. More

Medical Device News

@FierceMedDev: Cardiac Science sells off diagnostic biz, focuses on defibrillators. News | Follow @FierceMedDev

@MarkHFierce: Folks have figured out a way to goose Dx tech that could enable personalized prostate cancer treatments. Release | Follow @MarkHFierce

 @DamianFierce: Now, per Reuters, Thermo Fisher is in the lead with a $12B bid on Life Tech. More | Follow @DamianFierce

> Hitachi wins FDA nod for new CT scanner. News

> U.K. regulators issue alert over Hoya's intraocular lens implant. Article

> Is Abbott trying to buy its way back into the drug biz? Item

Biomarkers News

 @EmilyMFierce: New prostate cancer predictors revealed. Report | Follow @EmilyMFierce

> CV biomarker study finds evidence of bias, exaggeration in the field. Story

> French researchers cast doubt on chemo biomarker's viability. Item

> Biomarkers predict risk of diabetes-related kidney trouble. Article

> U.K. team concocts rapid approach for colorectal cancer biomarker detection. More

Drug Delivery News

@MichaelGFierce: Biogen Idec's new oral MS drug Tecfidera has an unknown mechanism of action, the company says. More | Follow @MichaelGFierce

> Cholesterol 'rafts' enable cancer-killing delivery of DNA, RNA. Report

> Analysts expect nanotech drug delivery boom despite safety concerns. Story

> Pozen seeks FDA approval for layered aspirin cardiovascular treatment. Item

> FDA rejects A.P. Pharma's delayed-onset chemo drug. More

> Entrega, other startups make strides in needle-free delivery. Article

And Finally... Feeling hungry may protect the brain against Alzheimer's. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.